Grant extra exclusivity only in exchange for binding low prices in poorer countries
Companies get longer monopolies for rare and paediatric cancer drugs. That reward should come with a commitment to sell at cost in low-income countries.
Orphan, paediatric and data exclusivity extensions are valuable regulatory rewards granted without access conditions. The proposal is that regulators condition these extensions on a registered commitment: tiered pricing at or near cost in all low- and lower-middle-income countries, filing for registration in those countries within a year of first approval, and participation in pooled procurement. Non-compliance would shorten the exclusivity. Similar conditionality is used in some public research funding agreements and in the EU's 2023 pharmaceutical reform proposals linking exclusivity to launch in all member states.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
Pages like this
not linked directly; found by shared links- IdeaA joint price negotiation bloc for middle-income countries, modelled on Beneluxa
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaBuy out the patent on a curative cancer drug and sell it at generic prices
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaTie WHO essential-medicines listing to a published tiered price and supply pledge
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaMedicines Patent Pool licences for every patented cancer drug on the WHO list
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaA Gavi-style pooled purchaser for radiotherapy equipment and service
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaPooled procurement and voluntary licensing for essential cancer medicines in low-income countries
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares Prices and value, Most of the world has almost no cancer care.